Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin vs Glimepiride in Metformin-Intolerant T2DM
NCT01863667Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin A1c at 54 weeks, Percentage of Participants Who Experienced at Least One Adverse Event at 57 weeks and 1 more. Started Jul 2013; status: terminated.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01863667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863667.